参考文献/References:
[1] Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy[J]. J Am Coll Cardiol,2010,56(24):2051-2066.
[2] Juurlink DN, Mhsc TG, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180(7):713-718.
[3] Martine G, Arnaud B, Christophe CJ, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized, double-blind OCLA( Omeprazole CLopidogrel Aspirin)study[J]. J Am Coll Cardiol,2008,51(3):256-260.
[4] Bhatt DL,Cryer BL,Contant CF,et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med,2010,363(20):1909-1917.
[5] Kazui M, Nishiya Y, Ishizuka T, et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos,2010,38(1):92-99.
[6] Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities[J]. Drug Metab Dispos,2004,32(8):821-827.
[7] Gilard M, Arnaud B, Legal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin[J]. J Thromb Haemost,2006,4(11):2508-2509.
[8] Park Y, Jung JM, Tantry US, et al. Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study[J]. J Atheroscler Thromb,2014,21(11):1121-1139.
[9] Small D, Farid N, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel[J]. J Clin Pharmacol,2008,48(4):475-484.
[10] Funck-brentano C, Szymezak J, Steichen O, et al.Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers[J]. Arch Cardiovasc Dis,2013,106(12):661-671.
[11] Siller-Matula J, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel[J]. Am Heart J,2009,157(1):148.e1-148.e5.
[12] Cuisset T, Frere C, Quilici J, et al.Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA(Proton Pump Inhibitors and Clopidogrel Association)prospective randomized study[J]. J Am Coll Cardiol,2009,54(13):1149-1153.
[13] Donoghue MLO, Braunwald E, Antman EM, et al.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials[J]. Lancet, 2009,374(9694):989-997.
[14] Gerson LB, Mcmahon D, Rockson SG. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature[J]. Dig Dis Sci,2012,57:1304-1313.
[15] Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis[J]. Int J Cardiol,2013,167(3):965-974.
[16] Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J]. Eur Heart J,2013,34:1708-1715.
[17] Sim S, Risinger C, Dahl M, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J]. Clin Pharmacol Ther,2006,79(1):103-113.
[18] Goldstein J, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations[J]. Pharmacogenetics,1997,7(1):59-64.
[19] Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J]. J Gastroenterol,2001,36(10):669-672.
[20] Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J,2009,30:916-922.
[21] Depta JP, Lenzini PA, Lanfear DE, et al.Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction[J]. Pharmacogenomics J,2014,28:1-6.
[22] Hokimoto S, Mizobe M, Akasaka T, et al. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation[J]. Thromb Res,2014,133(4):599-605.
[23] Huang B, Huang Y, Li Y, et al.Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis[J]. Arch Med Res,2012,43(3):212-224.
[24] Zou JJ, Chen SL, Tan J, et al. Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor[J]. PLoS One,2014,9(1):1-6.
[25] Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2007,50(19):1852-1856.
[26] Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:the PLATO( PLATelet inhibition and patient Outcomes )PLATELET substudy[J]. J Am Coll Cardiol,2010,56(18):1456-1462.
[27] Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor insights from the platelet inhibition and patient outcomes trial[J]. Circulation,2012,125:978-986.
[28] Gara PTO, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2013,127:e362-e425.
[29] Gurbel PA, Bliden KP, Fort JG, et al. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel[J]. Am Heart J,2013,165(2):176-182.
相似文献/References:
[1]陈艳,综述,袁晋青,等.替格瑞洛临床应用新进展[J].心血管病学进展,2016,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
CHEN Yan,YUAN Jinqing.The Updates of Ticagrelor Use in Clinical Practice[J].Advances in Cardiovascular Diseases,2016,(5):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
[2]袁德山,袁晋青.冠心病患者中基于基因检测的个体化抗血小板治疗最新研究进展[J].心血管病学进展,2019,(6):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
YUAN Deshan,YUAN Jinqing.Individualized Antiplatelet Therapy Based on Gene Testing in Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
[3]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(5):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[4]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(5):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[5]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(5):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]